Pharma Mar SAU (PHMMF PINK) stock market data APIs
$80.3776
0(0%)
as of May 16, 2025
Try our APIs with
free plan!
Pharma Mar SAU Financial Data Overview
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Prev. Close
80.3776
Open
80.3776
High
80.3776
Low
80.3776
52 wk Range
30.452-105.6
Market Cap
1 518 M
P/E Ratio
64.2143
Shares Outstanding
17 271 K
Revenue
176 M
EPS
-0.2365
Dividends (Yield)
0.0112
Beta
-0.064
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharma Mar SAU data using free add-ons & libraries
Get Pharma Mar SAU Fundamental Data
{
"General": {
"Code": "PHMMF",
"Type": "Common Stock",
"Name": "Pharma Mar SAU",
"Exchange": "PINK",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG00BBVVVW6",
"ISIN": "ES0169501022",
"CUSIP": null,
"CIK": null,
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": null,
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": null,
"IsDelisted": false,
"Description": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates ..."
}
}Pharma Mar SAU Fundamental data includes:
- Net Revenue: 176 M
- EBITDA: 11 726 K
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-21
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharma Mar SAU News
New
Exploring High Growth Tech Stocks In Europe May 2025
As European markets continue to navigate the complexities of global trade tensions, the pan-European STOXX Europe 600 Index has shown resilience, rising for a fourth consecutive week amid optimism for...
European Growth Companies Insiders Are Eager To Own
In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising 3.93% as investor sentiment was buoyed by the European Central Bank's rate cuts and a delay...
European Stocks That Investors Might Be Undervaluing
Amid recent trade uncertainties and economic shifts, European markets have seen a positive upswing, with the STOXX Europe 600 Index rising by nearly 4% as investor sentiment was buoyed by the European...
Exploring High Growth Tech Stocks in Europe April 2025
As European markets navigate the complexities of escalating global trade tensions, the pan-European STOXX Europe 600 Index recently saw a decline of 1.92%, reflecting broader concerns about economic g...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
